Once For All to Acquire Nalanda Global
4.4.2024 09:00:00 EEST | Business Wire | Press release
Once For All (the “Company”), a European leader in supply chain compliance and sustainable sourcing solutions for the built environment, is excited to announce the acquisition of Nalanda Global (“Nalanda”), a leading supply chain risk and compliance management software platform in Spain.
The transaction extends Once For All’s European footprint into Spain and enhances the differentiated offering of its technology platform, adding scale and the ability to aid in providing a broader product suite to its customer base. Similar to Once For All, Nalanda operates a SaaS-based network that helps enable contractors in multiple industries to manage the compliance of sub-contractors in their supply chain. Nalanda also brings additional worker-level compliance and health & safety solutions to Once For All’s product suite.
Founded in 2000 by a group of preeminent Spanish construction companies, Nalanda is based in Madrid, Spain, and its international presence currently extends across more than ten countries in Europe and Latin America. Its solutions are used by large companies across a variety of engineering-related sectors including construction and facilities management. With a network of over 1,000 contractors and 45,000 sub-contractors as of December 2023, Nalanda has one of the largest digital communities of suppliers globally.
GTCR, a leading private equity firm, acquired Once For All in 2023 in partnership with Chief Executive David Hornsby. PSG Equity, a growth equity firm that partners with software and technology-enabled services companies, acquired a majority stake in Nalanda in 2021. As part of the transaction, which is expected to close in the coming weeks, the PSG funds will retain a minority stake in the combined business.
David Hornsby, Chief Executive of Once For All, said:
“Nalanda is a well-established provider with a product suite that strategically complements our own, and we are enthusiastic about combining our strengths as we continue to grow Once For All across Europe. We are excited to welcome the Nalanda team to Once For All and we look forward to working together.”
Juan Gil Rabadan, Founder and CEO of Nalanda, said:
“Nalanda has gone through a transformative journey over the last three years under PSG’s ownership. Through the investment in people and product, both organically and via M&A, we’ve established Nalanda as an industry leader in supply chain risk and compliance management in Spain, with a growing international presence. We are now thrilled to join Once For All as we share a vision for supporting the built environment globally. We look forward to partnering with the Once For All team and continuing to invest in innovating our technology and capabilities to serve our customers.”
Mark Anderson, Managing Director and Head of Technology, Media & Telecommunications at GTCR, said:
“The combination of Once for All and Nalanda helps position the business for future growth through a pan-European offering. The combined company provides a leading technology platform and differentiated suite of products to help address the critical supply chain and compliance needs of its customers. We are pleased to partner with the PSG team and look forward to the continued success of the business.”
Dany Rammal, Managing Director at PSG Equity, said:
“PSG is proud to have been part of the journey to create a leading Spain-based software champion. Nalanda’s success to date is a testament to Juan Gil Rabadan’s vision and his entire team’s dedication to scaling the Company’s solution into a comprehensive supply chain risk management and compliance offering. We are excited to be continuing the journey alongside GTCR, David Hornsby and the entire Once For All management team in support of the combined company’s growth journey.”
About Once For All
Once For All is a European leader in supply chain risk management and sustainable sourcing solutions for the construction industry. We help our customers source and track sales opportunities, manage risk and compliance, and provide tools to increase efficiency in their supply chains. Once For All has over 150,000 customers that use its single codebase SaaS solution to search, find and assess future business relationships based on skills, trades and ESG credentials. As a result, Once For All manages one of the largest proprietary ESG data sets in the world. Once For All has over 400 employees, is the market leader in UK and France and has operations in Belgium and Germany. For more information, please visit www.onceforall.com.
About Nalanda Global
Nalanda is a Spanish supplier risk and compliance management platform founded in 2000. It leverages intelligent cloud software to help connect companies and suppliers using a digital platform that enables the smooth exchange and verification of health and safety, due diligence, supplier validation, invoices, ESG and other business information, as well as providing solutions designed to ensure compliance with worker access, and working time. Nalanda operates in Spain, as well as in several European and Latin American countries. For more information, please visit www.nalandaglobal.com.
About GTCR
Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $25 billion in over 270 companies, and the firm currently manages $40 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
About PSG Equity
PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 135 companies and facilitated 479 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Madrid, Paris and Tel-Aviv. To learn more about PSG, visit www.psgequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403942729/en/
Contact information
Once For All
Arun Varma
arun.varma@onceforall.com
Nalanda
Goodwill Comunicación
Javier Herreros
jherreros@goodwill.es
GTCR
Andrew Johnson
Andrew.johnson@gtcr.com
PSG Equity
Prosek Partners
Matthieu Roussellier/Kate Pledger
Pro-psg@prosek.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
